Anti-inflammatory effects of a p38 MAP kinase inhibitor, doramapimod, against bacterial cell wall toxins in equine whole blood

摘要

Doramapimod (BIRB-796-BS), is an anti-inflammatory compound, acting through p38 MAPK inhibition, but its anti-inflammatory effects have not previously been studied in the horse. Whole blood aliquots from healthy horses diluted 1:1 with cell culture medium were incubated for 21 h with 1 mu g/ml of lipopolysaccharide (LPS), lipoteichoic acid (LTA) or peptidoglycan (PGN) in the presence of increasing concentrations of doramapimod (3 x 10(-8) M to 10(-5) M). Cell bioassays were used to measure TNF-alpha and IL-1 beta activity. Doramapimod significantly and potently inhibited TNF-alpha and IL-1 beta activity induced by all three bacterial toxins. There was no significant difference in IC50 or maximum inhibition of TNF-alpha or IL-1 beta production between any of the toxins. Maximum inhibition of IL-1 beta was higher than that of TNF-alpha for all toxins, and this difference was significant for LPS (P = 0.04). Doramapimod was a potent inhibitor of TNF-alpha and IL-1 beta for inflammation induced by LPS, LTA and PGN, with potency much greater than that of other drugs previously tested using similar methods.